US10633363B2

EPAC1 activators as HIV latency reversal agents (LRA)

University of Texas System

Abstract

The invention relates generally to novel EPAC1 activators, such as Formula I and the preparation thereof as well as the use of EPAC1 activators as human immunodeficiency virus (HIV) latency reversal agents (LRAs).

University: University of Texas System
Assignee: The Board Of Regents Of The University Of Texas System
Inventor: Haitao Hu
Priority date: July 14, 2017
Filing date: July 13, 2018
Grant date: April 28, 2020
Publication date: April 28, 2020
Language: en
PDF source: https://patentimages.storage.googleapis.com/11/db/d4/91627dad8cb3fe/US10633363.pdf
Metadata fetched: August 29, 2026 00:27